skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Clinical utility of the risperidone formulations in the management of schizophrenia

Review

(1113) Views  (447) Full article downloads

Authors: Madaan V, Bestha DP, Kolli VB, Jauhari S, Burket RC

Published Date October 2011 Volume 2011:7(1) Pages 611 - 620
DOI: http://dx.doi.org/10.2147/NDT.S14385

Vishal Madaan1, Durga P Bestha2, Venkata Kolli2, Saurabh Jauhari2, Roger C Burket1
1University of Virginia Health System, Charlottesville, VA, USA; 2Creighton University Medical Center, Omaha, NE, USA

Abstract: Risperidone is one of the early second-generation antipsychotics that came into the limelight in the early 1990s. Both the oral and long-acting injectable formulations have been subject to numerous studies to assess their safety, efficacy, and tolerability. Risperidone is currently one of the most widely prescribed antipsychotic medications, used for both acute and long-term maintenance in schizophrenia. Risperidone has better efficacy in the treatment of psychotic symptoms than placebo and possibly many first-generation antipsychotics. Risperidone fares better than placebo and first-generation antipsychotics in the treatment of negative symptoms. Risperidone's long acting injectable preparation has been well tolerated and is often useful in patients with medication nonadherence. Risperidone has a higher risk of hyperprolactinemia comparable to first-generation antipsychotics (FGAs) but fares better than many second-generation antipsychotics with regards to metabolic side effects. In this article, we briefly review the recent literature exploring the role of risperidone formulations in schizophrenia, discuss clinical usage, and highlight the controversies and challenges associated with its use.

Keywords: risperidone, schizophrenia, formulation, antipsychotic, side effects







 

Other articles by Dr Vishal Madaan



Readers of this article also read: